Melanoma Focus appeal against the NICE Final Draft Guidance on Tebentafusp

Melanoma Focus appealed against the NICE Final Draft Guidance on tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441].

Tebentafusp is the only licensed treatment for metastatic uveal melanoma. For more info about the appeals process, see here: https://buff.ly/4910Lk3

To find out more information about tebentafusp see here.